Table 3. Adverse events per group by treatment.

	First dose				Second dose
Adverse event	5 µg	10 µg	20 µg	Placebo	5 µg	10 µg	20 µg	Placebo
Local reaction
Redness	2 (16.7; 0.16–1.00)	4 (33.3; 0.40–1.00)	9 (75.0; 0.66–1.00)	3 (25.0; 0.29–1.00)	8 (66.7; 0.63–1.00)	2 (16.7; 0.16–1.00)	5 (41.7; 0.48–1.00)	5 (41.7; 0.48–1.00)
Swelling	1 (8.3; 0.03–1.00)	0	4 (33.3; 0.40–1.00)	2 (16.7; 0.16–1.00)	2 (16.7; 0.16–1.00)	5 (41.7; 0.48–1.00)	1 (8.3; 0.03–1.00)	3 (25.0; 0.29–1.00)
Pain	11 (91.7; 0.72–1.00)	8 (66.7; 0.63–1.00)	8 (66.7; 0.63–1.00)	7 (58.3; 0.59–1.00)	9 (75.0; 0.66–1.00)	9 (75.0; 0.66–1.00)	8 (66.7; 0.63–1.00)	6 (50.0; 0.54–1.00)
Systemic reactions
Fever	0	0	0	0	0	0	0	0
Headache	4 (33.3; 0.40–1.00)	6 (50.0; 0.54–1.00)	2 (16.7; 0.16–1.00)	4 (33.3; 0.40–1.00)	6 (50.0; 0.54–1.00)	5 (41.7; 0.48–1.00)	1 (8.3; 0.03–1.00)	2 (16.7; 0.16–1.00)
Joint aches	0	1 (8.3; 0.03–1.00)	1 (8.3; 0.03–1.00)	0	0	2 (16.7; 0.16–1.00)	0	1 (8.3; 0.03–1.00)
Fatigue	0	4 (33.3; 0.40–1.00)	1 (8.3; 0.03–1.00)	1 (8.3; 0.03–1.00)	4 (33.3; 0.40–1.00)	3 (25.0; 0.29–1.00)	2 (16.7; 0.16–1.00)	2 (16.7; 0.16–1.00)
Muscle aches	2 (16.7; 0.16–1.00)	5 (41.7; 0.48–1.00)	2 (16.7; 0.16–1.00)	3 (25.0; 0.29–1.00)	1 (8.3; 0.03–1.00)	3 (25.0; 0.29–1.00)	0	0
Feeling of general discomfort	2 (16.7; 0.16–1.00)	2 (16.7; 0.16–1.00)	0	1 (8.3; 0.03–1.00)	2 (16.7; 0.16–1.00)	2 (16.7; 0.16–1.00)	0	0
Chills	0	2 (16.7; 0.16–1.00)	0	1 (8.3; 0.03–1.00)	1 (8.3; 0.03–1.00	1 (8.3; 0.03–1.00	0	0

Data are number(%; 95% CI). Adverse events up to 7 days after vaccination are reported.